Analyst Ratings for GlaxoSmithKline (GSK) [Sells]
GSK Rating Summary
GSK Price Target Summary
- Highest: $48.00 (Jefferies)
- Lowest: $44.00 (Morgan Stanley)
- Average: $46.00
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$46.00 (+7%)
* Over Last 12-Mos
Rating Score: 3.3 / 10 Percentile Rank: 30%
Rating Score: 3.3 / 10 Percentile Rank: 30%
Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
12/5/2022 | BofA Securities | Graham Perry | New Coverage | Underperform (N/A) |
36.00 (N/A) |
35.35 (42.99) |
21.61% | Details |
11/11/2022 | UBS | Michael Leuchten | Downgrade | Sell (Neutral) |
N/A (N/A) |
33.47 (42.99) |
28.44% | Details |
GSK Ratings News
- JPMorgan on GlaxoSmithKline (GSK:LN) (GSK): 'Dr. Sherbonou continues to see the ocular toxicity profile of Blenrep as challenging'
- Guggenheim Upgrades GlaxoSmithKline (GSK) to Buy, 'Vaccines, HIV, I&I, AND Oncology Set Up Improved 2024+ Growth'
- Guggenheim Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Buy
- See More